Literature DB >> 3169046

Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem.

R V Lewis1, N Irvine, D G McDevitt.   

Abstract

Six patients with chronic atrial fibrillation (AF) took single doses of digoxin, verapamil and diltiazem, alone and in combination. Three hours after dosing, resting and post-exercise heart rate, exercise tolerance and resting and post-exercise cardiac output were measured. Post-exercise heart rates ranged from 167 bpm (after placebo) to 122 bpm (after digoxin plus diltiazem) (P less than 0.05). However, the lower ventricular rates seen after treatment with the calcium antagonists were not associated with improved exercise tolerance, which did not differ significantly between the various treatments. Reduction of the ventricular rate was associated with a small increase in stroke volume but the benefits of this were offset by a rate related reduction in cardiac output. Further reduction of the rapid ventricular rates seen in digitalized patients with AF does not appear to be of benefit in terms of improving either exercise tolerance or cardiac output.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3169046     DOI: 10.1093/eurheartj/9.7.777

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  11 in total

Review 1.  [Drug therapy of tachycardic atrial arrhythmias].

Authors:  D Wietholt; H Gülker
Journal:  Med Klin (Munich)       Date:  1997-04-15

Review 2.  Atrial fibrillation. The therapeutic options.

Authors:  R V Lewis
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

3.  Atrial fibrillation begets trouble.

Authors:  J E Waktare; A J Camm
Journal:  Heart       Date:  1997-05       Impact factor: 5.994

4.  Importance of rate control or rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left ventricular function: a randomised controlled study.

Authors:  T Levy; S Walker; M Mason; P Spurrell; S Rex; S Brant; V Paul
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

5.  The drug treatment of atrial fibrillation.

Authors:  K S Channer
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

6.  What is meant by a "controlled" ventricular rate in atrial fibrillation?

Authors:  J M Rawles
Journal:  Br Heart J       Date:  1990-03

Review 7.  Atrial fibrillation: how to approach rate control.

Authors:  Lynda E Rosenfeld
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

Review 8.  Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.

Authors:  Naqash J Sethi; Emil E Nielsen; Sanam Safi; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

9.  The Relationship of Dehydration and Body Mass Index With the Occurrence of Atrial Fibrillation in Heart Failure Patients.

Authors:  Anna Chuda; Marcin Kaszkowiak; Maciej Banach; Marek Maciejewski; Agata Bielecka-Dabrowa
Journal:  Front Cardiovasc Med       Date:  2021-05-20

10.  A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.

Authors:  Dipak Kotecha; Melanie Calvert; Jonathan J Deeks; Michael Griffith; Paulus Kirchhof; Gregory Yh Lip; Samir Mehta; Gemma Slinn; Mary Stanbury; Richard P Steeds; Jonathan N Townend
Journal:  BMJ Open       Date:  2017-07-20       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.